

Notes of the meeting of the South and West Devon Formulary Interface Group

Tuesday 18th June 2013, 2pm – 4pm, The Watermark, Erme Court, Leonards Road, Ivybridge PL21 0SZ

| | | |
|------------------|---|-------------------------------|
| Present: | Chris Roome – Chair | NEW Devon CCG |
| | Phil Melluish – GP, Chair SDJF | South Devon CCG |
| | Larissa Sullivan – Interface Pharmacist | NEW Devon CCG |
| | Sarah Marner – Interface Pharmacist | NEW Devon CCG |
| | Carol Webb – Joint Formularies Technician | NEW Devon CCG |
| | Margaret Hinchliffe | Lay member |
| | Jeremy Morris – Formulary Pharmacist | Plymouth Hospitals NHS Trust |
| | Andrew Prowse – Assistant Director of Pharmacy | Plymouth Hospitals NHS Trust |
| | Gareth Franklin – Clinical Guidance Manager | NEW Devon CCG |
| | Iain Roberts – Lead MO Pharmacist | South Devon CCG |
| | Chris Sullivan – Prescribing Adviser | Devon Partnership Trust |
| | Amanda Gulbranson - Clinical Effectiveness Lead | Devon Partnership Trust |
| | Paul Hughes – Deputy Head of Prescribing | Kernow CCG |
| | Elena Mercer – Formulary Pharmacist | South Devon NHS Trust |
| | Karen O’Brian – Community Pharmacist | Devon LPC |
| | Rebecca Prosser – MO Pharmacist | South Devon CCG |
| | Paul Humphriss – Head of Medicines Management | South Devon NHS Trust |
| Apologies | Keith Gillespie – GP, Chair PAJF | NEW Devon CCG |
| | Petrina Trueman – Joint Formularies Pharmacist | NEW Devon CCG |
| | Steve Cooke – Pharmacy Manager | Plymouth Community Healthcare |
| | Mike Finnegan – Consultant, Chair PHNT DTC | Plymouth Hospitals NHS Trust |
| 1 | Welcome: The Chair welcomed everyone. Apologies as noted above. | |
| 2 | Notes and action log of last meeting 19th April 2013: These were noted and agreed. | |
| 3 | Summary of decision making process (including NHS England): The Chair outlined the processes involved. There was much discussion around the NHS England decisions and the uncertainty and frustrations the process is causing within the different organisations. There was discussion about the Clinical Policy Committee (CPC) decisions and how they are to be implemented locally and inclusion in the Formulary. These need to be implemented within a reasonable timeframe. There was discussion regarding the place of the Care Pathway Groups, these are contacted when an application is submitted to the CPC. It was highlighted that when a decision is made by the CPC it needs to be made clear that it is not included in the Formularies at that point, that further work is required. A statement such as ‘...is approved subject to its place in therapy being defined by the Formulary Interface Group’ could be included. The Chair agreed to include a | |

| | |
|-----------|--|
| | statement in these decision documents. |
| 4 | <p>Recent drug approvals (including NICE): These decisions were noted</p> |
| 5 | <p>Entry of NICE Technology Appraisals into the SW Formulary: This process detailed on the presented document was noted</p> |
| 6 | <p>MHRA Drug Safety Update – April and May: The content was discussed. The items that include secondary care drugs will be discussed at the Trusts Drugs & Therapeutic Committees. April: Concerns regarding strontium, these will be addressed with the review of osteoporosis treatments. Drug name confusions, zuclopenthixol was highlighted particularly. May: Nothing to be noted. There was discussion about how any information is highlighted to those concerned. Oksana Riley and Gail Foreshew are looking at producing a general governance and safety newsletter, Drug Safety Updates would be included in this. The LPC also produce a newsletter where these topics are highlighted.</p> |
| 7 | <p>Osteoporosis pathway: With the concerns highlighted regarding strontium the treatment pathways need minor revising. It is hoped that this work could produce a Devon wide pathway. Action: Osteoporosis pathway to be brought to the next meeting</p> |
| 8 | <p>Rivaroxaban for the treatment of DVT: The attached document had been produced by Plymouth and also a PGD. South Devon Haematologist looked at the document and made a few amendments. Plymouth are happy with the suggested amendments apart from the use of compression hosiery which is not part of the current recommendations. It is thought that South Devon wish to use rivaroxaban first-line, Plymouth and Cornwall would have rivaroxaban as an option. Action: To discuss with South Devon about the use of rivaroxaban first-line in the treatment of DVT.</p> |
| 9 | <p>Formulary issues / review work It was noted that the statin guidance in both the Plymouth and South Devon formularies is out of date. It was decided to look at this on the work-plan with the merger work. It was noted that Rebecca Bell, a pharmacist with SDTCCG is happy to be part of the work in merging the cardiology chapter. It was noted that the cost of sertraline has risen significantly.</p> |
| | Due to time Elena Mercer, Paul Hughes, Amanda Gulbranson, Chris Sullivan, Phil Melliush, Iain Roberts left the meeting at this point |
| 10 | <p>Formulary merger update:</p> <ul style="list-style-type: none"> ● Antibiotics: Graham Parsons is progressing with this piece of work, hoping to have it completed for the July meeting ● Pain: Rhys Ponton is to be taking this piece of work on. There was discussion about Palliative |

Care, this will be reviewed separately. It is hoped that palliative Care can be reviewed Devon wide with the Devon End of Life Committee, Paul Humphriss to link in with this

- **Wound management:** Paul Humphriss reported that this is being led by Theresa Mitchell. The work is on-going and hope to be able to bring information to the September FIG.

Due to time Sarah Marner, Larissa Sullivan, Rebecca Prosser, Paul Humphriss left the meeting at this point

11 Proposed SW formulary merger work plan, future meetings, ToR and membership:

It was noted that the merger needs to happen at pace, avoiding a full review of each chapter as both the current formularies are correct. If areas are highlighted for full review these will be slotted in to the end of the work plan.

It was asked that Jeremy Morris is copied into all communication for the merger of the chapters. This is to ensure that all appropriate clinicians are contacted and made aware.

Next meeting: Tuesday 16th July 2013, 2pm – 4pm, The Watermark, Erme Court, Leonards Road, Ivybridge PL21 0SZ

| South and West Devon Formulary Group – Action log | | | |
|---|--|-------------|-----------|
| Date | Action | Responsible | Completed |
| June 2013 | Revised Osteoporosis pathway to be brought to the next meeting | GF | |
| June 2013 | To discuss with South Devon about the use of rivaroxaban first-line in the treatment of DVT. | GF/LS | |
| | | | |